PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHydroxocobalamin
Cyanokit(hydroxocobalamin)
Cyanokit, Hydroxocobalamin (hydroxocobalamin) is a small molecule pharmaceutical. Hydroxocobalamin was first approved as Hydroxocobalamin on 1982-01-01. It is used to treat alcoholic neuropathy, diabetic neuropathies, multiple sclerosis, pernicious anemia, and poisoning in the USA. It has been approved in Europe to treat poisoning.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
chemically-induced disordersD064419
Trade Name
FDA
EMA
Cyanokit, Hydroxocobalamin (discontinued: Alpharedisol, Cyanokit, Hydroxocobalamin, Hydroxomin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxocobalamin
Tradename
Company
Number
Date
Products
CYANOKITBTGN-022041 RX2011-04-08
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aronamin goldunapproved drug other2018-12-12
cyanokitNew Drug Application2023-04-27
hydroxocobalaminunapproved drug other2026-05-15
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B03: Antianemic preparations
— B03B: Vitamin b12 and folic acid
— B03BA: Vitamin b12 (cyanocobalamin and analogues)
— B03BA03: Hydroxocobalamin
— B03BA53: Hydroxocobalamin, combinations
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB33: Hydroxocobalamin
HCPCS
No data
Clinical
Clinical Trials
755 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin b 12 deficiencyD014806EFO_0000734E53.824254960
AnemiaD000740EFO_0004272D64.9—4863652
Diabetic neuropathiesD003929EFO_1000783—13221017
Cognitive dysfunctionD060825—G31.8414—11117
Iron deficienciesD000090463—E61.1—1221317
Diabetes mellitusD003920EFO_0000400E08-E13—2221016
InflammationD007249MP_0001845—1——11416
HyperhomocysteinemiaD020138———1211216
Healthy volunteers/patients———22—11116
Iron-deficiency anemiaD018798—D50——131216
Show 67 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——65———9
Brain injuriesD001930—S06.921——35
MicronutrientsD018977———1——45
FibromyalgiaD005356EFO_0005687M79.121——35
Systemic lupus erythematosusD008180EFO_0002690M32—1——34
AffectD000339———1——34
Memory disordersD008569———1——34
Coronavirus infectionsD018352EFO_0007224B34.211——23
Sars-cov-2D000086402——22——13
Thyroid diseasesD013959—E00-E07—1——23
Show 71 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I101———45
Weight lossD015431——1———45
Heart failureD006333EFO_0003144I501———34
Colorectal neoplasmsD015179——1———23
Child developmentD002657——1———23
Sezary syndromeD012751—C84.12————2
Mycosis fungoidesD009182—C84.02————2
T-cell lymphoma cutaneousD016410—C84.A2————2
Multiple sclerosisD009103EFO_0003885G351———12
Cognition disordersD003072——1———12
Show 14 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Folic acid deficiencyD005494EFO_0001070E53.8————1212
Deglutition disordersD003680—R13.1————99
Gastroesophageal refluxD005764EFO_0003948K21————77
Gyrate atrophyD015799——————66
Metabolic syndromeD024821EFO_0000195E88.810————66
Vitamin a deficiencyD014802EFO_1001237E50————66
FatigueD005221—R53.83————55
InfectionsD007239EFO_0000544—————44
Nutritional statusD009752——————44
Metabolic diseasesD008659EFO_0000589E88.9————44
Show 244 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHydroxocobalamin
INNhydroxocobalamin
Description
Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is a vitamin found in food and used as a dietary supplement. As a supplement it is used to treat vitamin B12 deficiency including pernicious anemia. Other uses include treatment for cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. It is given by injection into a muscle or vein.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID13422-51-0
RxCUI—
ChEMBL IDCHEMBL2103737
ChEBI ID27786
PubChem CID44475014
DrugBankDB00200
UNII IDQ40X8H422O (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Hydroxocobalamin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,922 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
699 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use